Deuruxolitinib + Placebo
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Alopecia Areata
Conditions
Alopecia Areata
Trial Timeline
Aug 5, 2025 → May 1, 2028
NCT ID
NCT07133308About Deuruxolitinib + Placebo
Deuruxolitinib + Placebo is a phase 3 stage product being developed by Sun Pharmaceutical for Alopecia Areata. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07133308. Target conditions include Alopecia Areata.
What happened to similar drugs?
1 of 19 similar drugs in Alopecia Areata were approved
Approved (1) Terminated (0) Active (18)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07133308 | Phase 3 | Recruiting |
Competing Products
20 competing products in Alopecia Areata
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Baricitinib | Eli Lilly | Phase 2 | 42 |
| CTP-543 | Sun Pharmaceutical | Phase 2/3 | 42 |
| CTP-543 | Sun Pharmaceutical | Phase 3 | 40 |
| Baricitinib + Placebo | Eli Lilly | Phase 2/3 | 38 |
| Baricitinib 4 MG Oral Tablet | Eli Lilly | Approved | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 40 |
| minoxidil | Johnson & Johnson | Phase 3 | 40 |
| 5% Minoxidil + 2% Minoxidil | Johnson & Johnson | Phase 3 | 40 |
| Minoxidil + vehicle of 5% Minoxidil topical foam | Johnson & Johnson | Phase 2 | 35 |
| 5% Minoxidil Topical Foam + Vehicle Topical Foam | Johnson & Johnson | Phase 3 | 40 |
| Upadacitinib + Upadacitinib Placebo | AbbVie | Phase 3 | 47 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 47 |
| Secukinumab + Placebo | Novartis | Phase 2 | 27 |
| Daxdilimab | Amgen | Phase 2 | 35 |
| Ritlecitinib | Pfizer | Pre-clinical | 30 |
| LITFULO | Pfizer | Pre-clinical | 30 |
| Ritlecitinib | Pfizer | Pre-clinical | 33 |
| Ritlecitinib higher dose + Ritlecitinib lower dose + Placebo | Pfizer | Phase 3 | 47 |
| Ritlecitinib | Pfizer | Pre-clinical | 26 |